Literature DB >> 8484762

Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability.

P J Wood1, I J Stratford, G E Adams, C Szabo, C Thiemermann, J R Vane.   

Abstract

The nitric oxide donor, SIN-1 and nitric oxide synthase inhibitor, nitro-L-arginine were examined for their effects on energy metabolism using 31P magnetic resonance spectroscopy, and on radiation sensitivity in the transplantable murine tumour, SCCVII/Ha. SIN-1 at 2 mg/kg i.v. reduced Pi/total by 40-50% within 10 min and increased X-ray sensitivity 3 fold, consistent with increased tumour oxygenation. Nitro-L-arginine at 10 mg/kg i.v. increased Pi/total by 250% at 45 min and was maintained for at least 2 hr. Nitro-L-arginine also increased radiation resistance 3-5 fold, consistent with the induction of tumour hypoxia. The results indicate that tumour energy metabolism may be altered through drug induced modification of nitric oxide availability, and that these changes are sufficient to modify tumour sensitivity to X-rays.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8484762     DOI: 10.1006/bbrc.1993.1444

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Increased L-arginine transport in a nitric oxide-producing metastatic colon cancer cell line.

Authors:  J C Cendan; W W Souba; E M Copeland; D S Lind
Journal:  Ann Surg Oncol       Date:  1996-09       Impact factor: 5.344

2.  Radiation sensitisation by nitric oxide releasing agents.

Authors:  J B Mitchell; J A Cook; M C Krishna; W DeGraff; J Gamson; J Fisher; D Christodoulou; D A Wink
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  Growth inhibition and radiosensitization of cultured glioma cells by nitric oxide generating agents.

Authors:  M Kurimoto; S Endo; Y Hirashima; H Hamada; T Ogiichi; A Takaku
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

4.  Nitric oxide synthase is expressed in experimental malignant glioma and influences tumour blood flow.

Authors:  I R Whittle; F Collins; P A Kelly; I Ritchie; J W Ironside
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 5.  The reemergence of nitric oxide and cancer.

Authors:  David A Wink; Lisa A Ridnour; S Perwez Hussain; Curtis C Harris
Journal:  Nitric Oxide       Date:  2008-09       Impact factor: 4.427

Review 6.  Gasotransmitters in cancer: from pathophysiology to experimental therapy.

Authors:  Csaba Szabo
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

7.  Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1.

Authors:  P J Wood; J M Sansom; I J Stratford; G E Adams; C Szabo; C Thiemermann; J R Vane
Journal:  Br J Cancer Suppl       Date:  1996-07

8.  Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma.

Authors:  S Q Shan; G L Rosner; R D Braun; J Hahn; C Pearce; M W Dewhirst
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.

Authors:  S A Butler; P J Wood; S Cole; C Williams; G E Adams; I J Stratford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice.

Authors:  A Orucevic; P K Lala
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.